vaccines against chronic diseases
Company profile
Ticker
VAXX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Covaxx Brasil Ltda. • Trinity Property Group • United Neuroscience Limited • United Neuroscience Limited • United Neuroscience, LLC • UNS IP Holdings, LLC ...
IRS number
862083865
VAXX stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Feb 24
8-K
Departure of Directors or Certain Officers
1 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Changes in Registrant's Certifying Accountant
28 Sep 23
EFFECT
Notice of effectiveness
21 Aug 23
424B3
Prospectus supplement
18 Aug 23
CORRESP
Correspondence with SEC
15 Aug 23
Latest ownership filings
SC 13G/A
Reese Lou
12 Feb 24
SC 13G/A
Hu Mei Mei
12 Feb 24
SC 13G/A
Prime Movers Lab Fund I LP
7 Feb 24
144
Notice of proposed sale of securities
30 Jan 24
144
Notice of proposed sale of securities
30 Nov 23
144
Notice of proposed sale of securities
30 Nov 23
144
Notice of proposed sale of securities
29 Nov 23
144
Notice of proposed sale of securities
29 Nov 23
144
Notice of proposed sale of securities
21 Nov 23
144
Notice of proposed sale of securities
21 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.60 mm | 17.60 mm | 17.60 mm | 17.60 mm | 17.60 mm | 17.60 mm |
Cash burn (monthly) | 6.55 mm | 362.25 k | 4.48 mm | 5.63 mm | 4.39 mm | 4.99 mm |
Cash used (since last report) | 44.86 mm | 2.48 mm | 30.68 mm | 38.50 mm | 30.08 mm | 34.15 mm |
Cash remaining | -27.26 mm | 15.12 mm | -13.07 mm | -20.90 mm | -12.48 mm | -16.55 mm |
Runway (months of cash) | -4.2 | 41.7 | -2.9 | -3.7 | -2.8 | -3.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 8 |
Closed positions | 5 |
Increased positions | 13 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 16.24 bn |
Total shares | 183.12 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Prime Movers Lab Fund I | 113.30 mm | $0.00 |
United Biomedical | 57.88 mm | $0.00 |
Adage Capital Partners GP, L.L.C. | 3.00 mm | $4.11 bn |
BLK Blackrock | 2.53 mm | $3.46 bn |
Vanguard | 2.38 mm | $3.26 bn |
STT State Street | 832.47 k | $1.14 bn |
Geode Capital Management | 829.80 k | $1.14 bn |
BAC Bank Of America | 499.56 k | $684.39 mm |
NTRS Northern Trust | 351.81 k | $481.98 mm |
Creative Planning | 278.65 k | $381.75 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Oct 23 | Peter Powchik | Stock option Class A common stock | Grant | Acquire A | No | No | 1.27 | 159,744 | 202.87 k | 159,744 |
8 Sep 23 | Prime Movers Lab Fund I | Class A common stock | Sell | Dispose S | Yes | No | 1.67 | 10,349 | 17.28 k | 3,594,122 |
8 Sep 23 | Prime Movers Lab Fund I | Class A common stock | Sell | Dispose S | Yes | No | 1.67 | 4,217 | 7.04 k | 1,464,578 |
8 Sep 23 | Prime Movers Lab Fund I | Class A Common Stock | Sell | Dispose S | Yes | No | 1.67 | 2,395 | 4.00 k | 831,658 |
8 Sep 23 | Prime Movers Lab Fund I | Class A common stock | Sell | Dispose S | No | No | 1.67 | 25,089 | 41.90 k | 8,713,663 |
8 Sep 23 | Prime Movers Lab Fund I | Class A common stock | Sell | Dispose S | Yes | No | 1.67 | 5,911 | 9.87 k | 2,053,079 |
7 Sep 23 | Prime Movers Lab Fund I | Class A common stock | Sell | Dispose S | Yes | No | 1.7872 | 8,378 | 14.97 k | 3,604,471 |
7 Sep 23 | Prime Movers Lab Fund I | Class A common stock | Sell | Dispose S | Yes | No | 1.7872 | 3,413 | 6.10 k | 1,468,795 |
7 Sep 23 | Prime Movers Lab Fund I | Class A Common Stock | Sell | Dispose S | Yes | No | 1.7872 | 1,939 | 3.47 k | 834,053 |
7 Sep 23 | Prime Movers Lab Fund I | Class A Common Stock | Sell | Dispose S | No | No | 1.7872 | 20,312 | 36.30 k | 8,738,752 |
News
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
24 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
24 Apr 24
Why Vaxxinity (VAXX) Shares Are Volatile Today
23 Apr 24
S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings
22 Apr 24
Why Vaxxinity (VAXX) Shares Are Down Nearly 50%
22 Apr 24
Press releases
Vaxxinity Issues Shareholder Letter
19 Apr 24
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
19 Apr 24
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
28 Mar 24
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
27 Mar 24
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024
7 Mar 24